Dosing & Uses
AdultPediatric
Rett Syndrome
Pending FDA approval for treatment of Rett syndrome
Rett Syndrome
Pending FDA approval for treatment of Rett syndrome in adults and children aged ≥2 years
Next:
Pharmacology
Mechanism of Action
Synthetic analog of the amino‐terminal tripeptide of insulin-like growth factor (IGF-1) designed to treat the core symptoms of Rett syndrome by potentially reducing neuroinflammation and supporting synaptic function
IGF-1 is produced by both of the major types of brain cells – neurons and glia; IGF-1 in the brain is critical for both normal development and for response to injury and disease
Trofinetide has been shown to inhibit the production of inflammatory cytokines, inhibit overactivation of microglia and astrocytes, and increase amount of available IGF-1 that can bind to IGF-1 receptors
Previous
Next:
Images
Pricing & Images are not currently available for this monograph.
Previous
Next:
Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.
